Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

JAKAVI® is available in four tablet strengths to enable dose optimisation for each patient1

The recommended starting dose for JAKAVI® is based on a patient’s platelet count at treatment initiation.1

  • 5 mg twice daily for patients with a platelet count between 50,000/mm3 and <75,000/mm3
  • 10 mg twice daily for patients with a platelet count between 75,000/mm3 and <100,000/mm3
  • 15 mg twice daily for patients with a platelet count between 100,000/mm3 and 200,000/mm3
  • 20 mg twice daily for patients with a platelet count of >200,000/mm3

 

Image showing dosing tablets at various strengths

 

Optimise your patients’ response to therapy with dose titration that’s based on efficacy and safety1

Infographic showing patients' response to therapy

Treatment may continue as long as benefit-risk balance remains positive. After interruption or discontinuation of JAKAVI® dosing, symptoms of myelofibrosis may return over a period of approximately 1 week. Unless abrupt discontinuation is required, gradual tapering of the dose may be considered, although the utility of tapering is unproven. Refer to the full Summary of Product Characteristics for further management guidance.1

Image of two people eating
 

 

Active monitoring can help you find a patient’s
optimal JAKAVI® dose.1

 

JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1

*For the full list of AEs, please refer to the SmPC.1

AE, adverse event; SmPC, summary of product characteristics.

  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
  2. Polverelli N, et al. EHA 2016, 9–12 June; Copenhagen, Denmark. Abstract P672.
  3. Harrison C, et al. N Engl J Med 2012;366:787–798.
  4. Verstovsek S, et al. Haematologica 2013;98:1865–1871.

Download the JAKAVI® treatment timeline
to use during your patient consultations

 

A manageable safety profile for your patients

 
Rate this content: 
No votes yet
UK | February 2022 | 185119
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]